• Title/Summary/Keyword: Oral Vaccine

Search Result 146, Processing Time 0.026 seconds

Studies on Development of Escherichia coli Subunit Vaccine against Calf Diarrhea; II. Immunogenicity and Protective Efficacy of Escherichia coli K99 and F41 Pilus Vaccines in Experimental Animals (송아지 대장균(大腸菌) Pilus Vaccine 개발(開發)에 관한 연구(硏究): II. 시험(試驗)백신의 면역원성(免疫原性) 및 방어효과(防禦效果))

  • Kim, Jong-man;Yoon, Young-dhuk;Park, Jeung-moon;Kim, Bong-hwan
    • Korean Journal of Veterinary Research
    • /
    • v.26 no.1
    • /
    • pp.103-108
    • /
    • 1986
  • The oil emulsion and alhydrogel pilli vaccines were prepared from a strain(O9: K35, K99, F41) of enterotoxigenic Escherichia coli isolated from calves with diarrhea and their immunogenicity was tested in guinea-pigs, pregnant goats and cows. Serum antibody responses to K99 and F41 antigens in guinea-pigs given experimental oil and gel vaccines peaked at 4 and 6 weeks after vaccinations. At that time, the mean hemagglutination inhibition titers to K99 and F41 antigens in guinea-pigs given oil vaccine were 1:25 and 1:1, 218 and those given gel vaccine were 1:54 and 1:724 respectively. Agglutinin titers in pregnant goats given the oil vaccine were significantly higher(mean 1:2,347) compared to those of control group(mean 1:160). Less than 12.5% of goatlings from vaccinated goats developed scours compared to nearly 100% in control group after oral challenge with enterotoxigenic Escherichia coil within 24 hours after birth. The highest agglutinin titers of cow serum and colostrum and of the serum of calves 48 hours after birth from cows given oil vaccine were 1:256, 1:512 and 1:64 respectively. On the other hand, those titers of serum and colostrum and of the serum of nursing calves from nonvaccinated cows were 1:8, 1:16 and 1:20 respectively. The protective efficacy of the oil emulsion vaccine was 72.1% under field conditions. These results strongly indicated that the vaccine could be applied for protection of diarrhea caused by enterotoxigenic Escherichia coli in calves.

  • PDF

Adjuvanticity of Processed Aloe vera gel for Influenza Vaccination in Mice

  • Eun-Jung Song;Erica Espano;Jeong-Hyun Nam;Jiyeon Kim;Kyu-Suk Shim;Eunju Shin;Young In Park;Chong-Kil Lee;Jeong-Ki Kim
    • IMMUNE NETWORK
    • /
    • v.20 no.4
    • /
    • pp.31.1-31.14
    • /
    • 2020
  • The effectiveness of current influenza vaccines is considered suboptimal, and 1 way to improve the vaccines is using adjuvants. However, the current pool of adjuvants used in influenza vaccination is limited due to safety concerns. Aloe vera, or aloe, has been shown to have immunomodulatory functions and to be safe for oral intake. In this study, we explored the potential of orally administered processed Aloe vera gel (PAG) as an adjuvant for influenza vaccines in C57BL/6 mice. We first evaluated its adjuvanticity with a split-type pandemic H1N1 (pH1N1) Ag by subjecting the mice to lethal homologous influenza challenge. Oral PAG administration with the pH1N1 Ag increased survival rates in mice to levels similar to those of alum and MF59, which are currently used as adjuvants in influenza vaccine formulations. Similarly, oral PAG administration improved the survival of mice immunized with a commercial trivalent influenza vaccine against lethal homologous and heterologous virus challenge. PAG also increased hemagglutination inhibition and virus neutralization Ab titers against homologous and heterologous influenza strains following immunization with the split-type pH1N1 Ag or the commercial trivalent vaccine. Therefore, this study demonstrates that PAG may potentially be used as an adjuvant for influenza vaccines.

Vaccination of Shrimp (Penaeus chinensis) against White Spot Syndrome Virus (WSSV)

  • Ha, Yu-Mi;Gong, Soo-Jung;Nguyen, Thi-Hoai;Ra, Chae-Hun;Kim, Ki-Hong;Nam, Yoon-Kwon;Kim, Sung-Koo
    • Journal of Microbiology and Biotechnology
    • /
    • v.18 no.5
    • /
    • pp.964-967
    • /
    • 2008
  • Two structural protein genes, VP19 and VP466, of white spot syndrome virus (WSSV) were cloned and expressed in Sf21 insect cells using a baculovirus expression system for the development of injection and oral feeding vaccines against WSSV for shrimps. The cumulative mortalities of the shrimps vaccinated by the injection of rVP19 and rVP466 at 15 days after the challenge with WSSV were 50.2% and 51.8%, respectively. For the vaccination by oral feeding of rVP19 and rVP466, the cumulative mortalities were 49.2% and 89.2%, respectively. These results show that protection against WSSV can be generated in the shrimp, using the viral structural protein as a protein vaccine.

The Mucosal Immune System for the Development of New Generation Vaccine

  • Yuki, Yoshikazu;Kiyono, Hiroshi
    • Proceedings of the Korean Society for Applied Microbiology Conference
    • /
    • 2003.06a
    • /
    • pp.55-62
    • /
    • 2003
  • The mucosal immune system provides a first line of defense against invasion of infectious agents via inhalation, ingestion and sexual contact. For the induction of protective immunity at these invasion sites, one must consider the use of the CMIS, which interconnects inductive tissues, including PP and NALT, and effector tissues of the intestinal, respiratory and genitourinary tracts. In order for the CMIS to induce maximal protective mucosal immunity, co-administration of mucosal adjuvant or use of mucosal antigen delivery vehicle has been shown to be essential. When vaccine antigen is administered via oral or nasal route, antigen-specific Th 1 and Th2 cells, cytotoxic T lymphocytes(CTLs) and IgA B cell responses are effectively induced by the CMIS. In the early stages of induction of mucosal immune response, the uptake of orally or nasally administered antigens is achieved through a unique set of antigen-sampling cells, M cells located in follicle-associated epithelium(FAE) of inductive sites. After successful uptake, the antigens are immediately processed and presented by the underlying DCs for the generation of antigen-specific T cells and IgA committed B cells. These antigen-specific lymphocytes are then home to the distant mucosal effector tissues for the induction of antigen-specific humoral(e.g., IgA) and cell-mediated (e.g., CTL and Th1) immune responses in order to form the first line of defense. Elucidation of the molecular/cellular characteristics of the immunological sequence of mucosal immune response beginning from the antigen sampling and processing/presentation by M cells and mucosal DCs followed by the effector phase with antigen-specific lymphocytes will greatly facilitate the design of a new generation of effective mucosal antigen-specific lymphocytes will greatly facilitate the design of a new generation of a new generation of effective mucosal adjuvants and of a vaccine deliver vehicle that maximizes the use of the CMIS.

  • PDF

Efficacy of alginate microsphere oral vaccine against Miamiensis avidus (Ciliophora: Scuticociliatida) in olive flounder (Paralichthys olivaceus) (알지네이트 코팅 Miamiensis avidus (Ciliophora: Scuticociliatida) 경구백신의 넙치(Paralichthys olivaceus)에 대한 효능평가)

  • Su-Mi Shin;Sung-Ju Jung
    • Journal of fish pathology
    • /
    • v.36 no.2
    • /
    • pp.311-321
    • /
    • 2023
  • The efficacy of the alginate microsphere (Alginate MS) oral vaccine against Miamiensis avidus in olive flounder (Paralichthys olivaceus) was confirmed through challenge infections by both immersion and injection routes. In trial 1, the formalin-inactivated M. avidus coated with alginate, designated as 'IMa+Alginate MS' group, and the IMa group were administered with vaccines mixed with feed, with a total antigen dose of 3.75 × 106 cells/fish. When challenged with immersion infection at five weeks post vaccination, the relative percent survival (RPS) in the IMa+Alginate MS group was 50% (immersed in 50% seawater) and 37.5% (immersed in 100% seawater). The group that received only IMa showed a low survival rate. In trial 2, the antigen was fed mixed with feed at a total dose of 2.38 × 106 cells/fish for 5 days. Two weeks after oral vaccination, fish were intraperitoneally injected for infection. The RPS in the IMa+Alginate MS group was 30.8%, while the IMa-only group showed no vaccine efficacy. At five weeks post vaccination, when subjected to challenge infection by immersion in 50% seawater, the IMa+Alginate MS group recorded a RPS of 42.9%, whereas the IMa group had a RPS of 14.3%. The results of this study indicate that coating M. avidus antigen with alginate can provide higher protection in olive flounder compared to administering the antigen alone.

Rotavirus Vaccines (로타바이러스 백신)

  • Koh, Hong
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • v.12 no.sup1
    • /
    • pp.72-76
    • /
    • 2009
  • Rotavirus infection is the leading cause of severe diarrhea disease in infants and young children worldwide. Rotavirus infects every child at least once by her/his $5^{th}$ birthday. It has been known that single episode of rotavirus infection can protect or alleviate subsequent illness caused by both homotypic and heterotypic rotaviruses. There are two currently licensed rotavirus vaccines. One is human-bovine rotavirus reassortant pentavalent vaccine ($RotaTeq^{TM}$), which contains five reassortant rotavirus (expressing protein G1, G2, G3, G4 and P[8]) and was licensed in Korea for use among infants in 2007. Another is live-attenuated human rotavirus vaccine ($Rotarix^{TM}$) derived from 89-12 strain which represents the most common of the human rotavirus VP7(G1) and VP4(P[8]) antigens. $Rotarix^{TM}$ was licensed in Korea in 2008. Both live oral rotavirus vaccines are efficacious in preventing severe rotavirus gastroenteritis.

Acute and subacute toxicity studies of GX-12, a DNA vaccine for the treatment of HIV infection, in SD rats

  • Park, Seul-Min;Kang, Kyung-Koo;Sohn, Yong-Sung;Kim, Mi-Ju;Baik, Dae-Hyun;Ahn, Byung-Ok;Kim, Won-Bae
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2002.11b
    • /
    • pp.157-157
    • /
    • 2002
  • The toxicity of GX-12, a naked DNA vaccine developed by research team of Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection, was investigated in Sprague-Dawley rats. In single-dose intramuscular/oral acute toxicity studies, animals were treated 0, 250, 1000 or 4000 $\mu\textrm{g}$/kg/$m\ell$ in sodium phosphate buffer.(omitted)

  • PDF

Generation of antibodies against N-terminus fragment of AgI/II protein from Streptococcus mutans GS-5 (연쇄상구균(Streptococcus mutans GS-5)의 항원단백질 AgI/II의 N-terminus절편에 대한 항체형성)

  • Han, Ji-Hye;Baik, Byeong-Ju;Yang, Yeon-Mi;Park, Jeong-Yeol;Kim, Jae-Gon
    • Journal of the korean academy of Pediatric Dentistry
    • /
    • v.33 no.3
    • /
    • pp.401-410
    • /
    • 2006
  • Dental caries results from localized demineralization of tooth enamel by acids of bacterial origin produced from the fermentation of dietary sugars. A group of related oral bacteria, collectively known as mutans streptococci, are implicated as the primary etiological agents of human caries. Within this group, Streptococcus mutans has been known as a causative agent for dental caries. As well as acid production yielding the demineralization of tooth enamel, adherence and colonization of S. mutans to the teeth are also important for their virulence Cell-surface fibrillar proteins, which mediate adherence to the salivary pellicle are virulence components of mutans streptococci, and primary candidates for a human caries vaccine. Here we report that the AgI/II gene from S. mutans GS-5 were cloned by PCR amplification of the bacterial chromosomal DNA and the integrity of cloned genes were confirmed by nucleotide sequencing. Sequence analyses showed the sequence alignment of 280 nucleotides between the cloned AgI/II and the reported sequence of S. mutans GS-5 showed the perfect match The cloned genes which signal nucleotide was truncated, were transferred into bacterial expression vector and the recombinant proteins were purified as His-tag fusion proteins In order to generate polyclonal antibodies against the recombinant proteins, AgI/II mr, some $100{\mu}g$ of the proteins was injected into mice three times. It can be used for an effective vaccine production to prevent dental caries caused by pathogenic S. mutans.

  • PDF

A Case Report of Tetanus Patient Showing Trismus and Dysphagia as Early Symptoms

  • Jang, Seo-Hee;Byun, Jin-Seok;Jung, Jae-Kwang;Choi, Jae-Kap
    • Journal of Oral Medicine and Pain
    • /
    • v.45 no.3
    • /
    • pp.79-82
    • /
    • 2020
  • Tetanus is a fatal disease caused by the infection Clostridium tetani found in animal feces and soil. It is a vaccine-preventable disease and rarely occurs in developed countries. However, approximately 30 cases still occur annually in South Korea. Tetanus, commonly called lockjaw, cause contraction of the masseter muscles in the early stage, resulting in trismus as the first symptom. As it progresses, spasm extends to various muscles in the face, neck, shoulder, and back, leading to distorted facial expression, dysphagia, backward arching of the body, dyspnea, and even death. Early diagnosis of tetanus is critical because it can quickly become fatal if left untreated. We present a case of trismus caused by tetanus and emphasize the importance of early diagnosis of acute trismus.